Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity

Neuroscience

Volumn 167, Issue 4, 2010, Pages 985-993

  Dluzen, D E ^a   McDermott, J L ^a   Darvesh, A S ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeast Ohio Medical University   (United States)

Author keywords

Gender differences; Neurodegeneration; Neuroprotection; Nigrostriatal; Testosterone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; METHAMPHETAMINE; SODIUM CHLORIDE; TESTOSTERONE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN SLICE; BRAIN WEIGHT; CONTROLLED STUDY; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SEX DIFFERENCE; STRIATE CORTEX; TIME;

3,4-DIHYDROXYPHENYLACETIC ACID; AGE FACTORS; ANIMALS; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; FEMALE; MALE; METHAMPHETAMINE; MICE; NEUROTOXICITY SYNDROMES; SEX FACTORS; TIME FACTORS;

EID: 77952545843     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.02.076     Document Type: Article

References (42)

1. Anderson L.I., Leipheimer R.E., Dluzen D.E. Effect of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice. Neuroscience 2005, 130:369-382.
2. Brecht M.L., O'Brein A., von Mayrhauser C., Anglin M.D. Methamphetamine use behaviors and gender differences. Addict Behav 2004, 29:89-106.
3. Brooks W.J., Jarvis M.F., Wagner G.C. Influence of sex, age and strain of MPTP-induced neurotoxicity. Res Commun Subst Abuse 1989, 10:181-184.
4. Cadet J.L., Krasnova I.N., Jayanthi S., Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007, 11:183-202.
5. Cappon G.D., Morforf L.L., Vorhees C.V. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response. Dev Brain Res 1997, 103:155-162.
6. Dluzen D.E. The effect of gender and the neurotrophin, BDNF, uponmethamphetamine-induced neurotoxicity of the nigrostriatal dopaminergic system in mice. Neurosci Lett 2004, 359:135-138.
7. Dluzen D.E., Anderson L.I., Pilati C.F. Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol Teratol 2002, 24:267-273.
8. Dluzen D.E., Horstink M. Estrogen as a neuroprotectant of the nigrostriatal dopaminergic system. Endocrine 2003, 21:67-75.
9. Dluzen D.E., Liu B. Gender differences in methamphetamine use and responses. Gend Med 2008, 5:24-35.
10. Dluzen D.E., McDermott J.L. Estrogen, anti-estrogen and gender differences in methamphetamine neurotoxicity. Ann N Y Acad Sci 2002, 965:135-156.
11. Dluzen D.E., McDermott J.L., Anderson L.I. Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001, 13:618-624.
12. Dluzen D.E., Salvaterra T.J. Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: comparisons with potassium-evoked output and responses in prepubertal mice. Neuroendocrinology 2005, 82:78-86.
13. Dluzen D.E., Tweed C., Anderson L.I., Laping N.J. Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 2003, 77:232-238.
14. Freyaldenhoven T.E., Cadet J.L., Ali S.F. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent. Brain Res 1996, 735:232-238.
15. Hall J.N., Broderick P.M. Community networks for response to abuse outbreaks of methamphetamine and its analogs. NIDA Res Monogr 1991, 115:109-120.
16. Heller A., Bubla N., Lew R., Heller B., Won L. Gender dependent enhanced adult neurotoxic response to methamphetamine following fetal exposure to the drug. J Pharmacol Exp Ther 2001, 298:769-779.
17. Hser Y.I., Evans E., Huang Y.C. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat 2005, 28:77-85.
18. Imam S.Z., Ali S.F. Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J Neurochem 2001, 78:952-959.
19. Irvine M. Meth becoming drug of choice among teens 2005, News Tribune, April 11.
20. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future national survey results on drug use, 1975-2007, Vol. 1: secondary school studies 2008, NIDA, Bethesda, MD, NIH Publication No. 08-6418A.
21. Kokoshka J.M., Fleckenstein A.E., Wilkins D.G., Hanson G.R. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem 2000, 75:2095-2102.
22. Kunnathur V., Shemisa K., Liu B., Salvaterra T.J., Dluzen D.E. Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine. Neurotoxicol Teratol 2006, 28:557-562.
23. Lewis C., Dluzen D.E. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci Lett 2008, 448:130-133.
24. Lin S.K., Ball D., Hsiao C.C., Chiang Y.L., Ree S.C., Chen C.K. Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci 2004, 58:206-212.
25. Liu B., Dluzen D.E. Gender differences in methamphetamine use and effects: clinical and experimental evidence. Drug and alcohol abuse research focus 2007, 63-88. Nova Science Publishers, New York. T.A. Walcott (Ed.).
26. Miller D.B., Ali S.F., O'Callaghan J.P., Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 1998, 844:153-165.
27. Miller D.B., O'Callaghan J.P. The role of temperature, stress and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 1995, 11:177-192.
28. Miller D.B., O'Callaghan J.P., Ali S.F. Age as susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. Ann N Y Acad Sci 2000, 914:194-207.
29. Miura H., Fujiki M., Shibata A., Ishikawa K. Prevalence and profile of methamphetamine users in adolescents and at juvenile classification home. Psychiatry Clin Neurosci 2006, 60:352-357.
30. Office of National Drug Control Policy 2003, 1-54. National Drug Control Strategy, February.
31. Pu C., Vorhees C.V. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev Brain Res 1993, 72:325-328.
32. Riddle E.L., Fleckenstein A.N., Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J 2006, 8:E413-E418.
33. Russell K., Dryden D.M., Liang Y., Friesen C., O'Gorman K., Durec T., Wild T.C., Klassen T.P. Risk factors for methamphetamine use in youth: a systematic review. BMC Pediatr 2008, 8:48-57.
34. Teuchert-Noodt G., Dawirs R.R. Age-related toxicity in prefrontal cortex and caudate-putamen complex of gerbils (Meriones unguiculatus) after a single dose of methamphetamine. Neuropharmacology 1991, 30:733-743.
35. Truong J.G., Wilkins D.G., Baudys J., Crouch D.J., Johnson-Davis K.L., Gibb J.W., Hanson G.R., Fleckenstein A.E. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther 2005, 314:1087-1092.
36. Volz T.J., Farnsworth S.J., Rowley S.D., Hanson G.R., Fleckenstein A.E. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 2009, 63:147-151.
37. Wagner G.C., Tekirian T.L., Cheo C.T. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm 1993, 93:67-70.
38. Westermeyer J., Boedicker A.E. Course, severity and treatment of substance abuse among women versus men. Am J Drug Alcohol Abuse 2000, 26:523-535.
39. Wu L.T., Pilowsky D.J., Schlenger W.E., Galvin D.M. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community. Drug Alcohol Depend 2007, 89:195-205.
40. Yu L., Kuo Y., Cheng C.G., Chen H.H., Hsu C.H. Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002, 75:282-287.
41. Yu L., Liao P.C. Estrogen and progesterone distinctly modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 2000, 107:1139-1147.
42. Yu Y.L., Wagner G.C. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J Neural Transm Park Dis Dement Sect 1994, 8:215-221.